Angiotech's resorbable sutures:
This article was originally published in Clinica
Executive Summary
Angiotech Pharmaceuticals has received 510(k) clearance from the US FDA for its resorbable sutures product line - Quill SRS Monoderm. The products, part of the company's larger "Quill" range of self-retaining system (SRS) sutures, are made from a rapidly absorbing polymer, and are indicated for use primarily in superficial wound closure. The Vancouver, Canada firm hopes to launch the product line in the US this autumn. The Quill SRS range of sutures incorporates a patented helical barbed design which obviates the need to tie knots to hold sutures in place. Angiotech also gained 510(k) clearance to market additional diameters of its Quill SRS Polydioxanone (PDO) product line - longer-lasting absorbable sutures typically used for deeper tissue closure.